The Lyon-based biotech PK MED, which manufactures micro-implants that allow molecules to be released in a controlled and localized manner, has just received €1.5 million in aid from Bpifrance to accelerate a program to improve bone marrow transplants.
PK MED receives €1.5M DeepTech non-dilutive financing from Bpifrance for the development of a local cell-homing implant to enhance bone marrow transplantation.
PK MED announces FDA clearance to initiate its clinical program for PKM-01, targeting local treatment of gout flares, directly commencing with a Phase 2 trial.
PK MED is proud to receive support from the Auvergne-Rhône-Alpes Region as part of the development of its activities. As France’s 2nd leading region for research and the 5th in Europe, it offers a dynamic innovation ecosystem with over 600 laboratories and 40,000 researchers.
